Skip to content


Xcopri, Ontozry (cenobamate) is a small molecule pharmaceutical. Cenobamate was first approved as Xcopri on 2020-03-10. It is used to treat partial epilepsies in the USA. It has been approved in Europe to treat epilepsy. It is known to target gamma-aminobutyric acid receptor subunit alpha-4 and gamma-aminobutyric acid receptor subunit alpha-6. Xcopri maintenance pack's patent is valid until 2027-10-30 (FDA).
Trade Name Ontozry
Common Name Cenobamate
Indication epilepsy, partial epilepsies
Drug Class Tranquilizers/antiepileptics (propanediol and pentanediol groups)
Get full access now